#Spain #Ampersand Capital #VIVEbiotech #Lentiviral Vector #San Sebastián

VIVEbiotech Partners with Ampersand Capital for Growth

On December 4, 2024, VIVEbiotech, a prominent player in the field of lentiviral vector contract development and manufacturing, announced its partnership with Ampersand Capital Partners. This partnership, marked by significant growth equity investment, aims to expand VIVEbiotech's manufacturing capabilities in San Sebastián, Spain, enhancing its ability to meet increasing demand in the gene and cell therapy sectors.

The investment from Ampersand is a strategic move that enables VIVEbiotech to bolster its resources and operational capacity as it continues to develop a robust pipeline of projects for clients focused on innovative in vivo and ex vivo cell and gene therapies. The company's state-of-the-art facility spans 3,000 square meters and is compliant with good manufacturing practices (GMP), promising high-quality output that adheres to international standards.

VIVEbiotech specializes in lentiviral vector production, offering comprehensive process development, manufacturing, and analytical testing services for leading biopharmaceutical companies. The company prides itself on its proprietary lentiviral vector platform, which facilitates custom development and manufacturing tailored to client needs. This technical expertise is further supported by VIVEbiotech’s skilled workforce, with over 140 highly qualified professionals, the majority holding advanced scientific degrees.

CEO Jon Alberdi expressed his enthusiasm for the collaboration, stating, “We are thrilled to welcome Ampersand as a key partner to accelerate VIVEbiotech's ambitious growth plan while strengthening our flexible, plug-and-play platform.” He believes that the alliance will allow VIVEbiotech to exceed its customers' expectations and continue leading the market.

The strategic investment will also see Dr. Stefan Beyer, an experienced veteran in the pharmaceutical outsourcing industry, appointed as Chairman of VIVEbiotech. Dr. Beyer underscored the promising trajectory of cell and gene therapies, noting, “Given the ongoing rapid growth of the cell and gene therapy sector, I am excited to join the VIVEbiotech team. Clients are drawn to the team's scientific expertise, and this investment by Ampersand will enable continued development for VIVEbiotech.”

The cell and gene therapy markets are burgeoning, with increasing interest in advanced therapeutic strategies. VIVEbiotech's commitment to innovative manufacturing aligns well with industry needs. The strategic enhancements enabled by the Ampersand partnership will likely position VIVEbiotech as a premier choice for companies focused on developing transformative therapies for serious medical conditions.

Marina Pellon-Consunji, a Partner at Ampersand, highlighted the potential of this investment: “We are thrilled to support VIVEbiotech in their mission to advance lentiviral vector development. The team's innovative approach makes them a key player in the growing cell and gene therapy industry.”

Founded in 2015, VIVEbiotech operates under strict EMA and FDA guidelines, collaborating with over 40 biotech companies worldwide. The organization's continued focus on scalable, high-yield production reflects its dedication to leading in the evolving field of biopharmaceuticals, particularly in the domains of cancer treatment and rare disease therapies.

This collaboration is poised to leverage the strengths of both organizations, driving VIVEbiotech towards further achievements in lentiviral vector production. With significant resources now at their disposal, VIVEbiotech is set to advance its capabilities on a global scale, ensuring it meets the accelerating demands of the biopharmaceutical industry. As this partnership matures, VIVEbiotech is expected to emerge as a pillar in the lentiviral vector manufacturing landscape, ultimately enhancing patient outcomes through cutting-edge therapeutic solutions.